In the Lidoderm case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo’s 5% lidocaine patch, Lidoderm. The case alleges that Endo paid its would-be generic competitor, Watson (now known as Actavis) hundreds of millions of dollars to delay entering the market with less-expensive generic versions of Lidoderm for 13 months, forcing direct purchasers to pay higher branded prices rather than lower generic prices for 13 months longer than they otherwise would have. Lidoderm had annual sales of over $1 billion during the relevant time, making the overcharge paid by direct purchasers quite substantial. On May 21, 2014, Faruqi & Faruqi was appointed co-lead counsel by the Court. The case settled for $166 million in early 2018.
NOTICE OF CLASS CERTIFICATION AND OPT OUT DEADLINE
Under “Case Details” below, please click on the links to see the official class certification notice, the second consolidated amended class action complaint, and the district court’s order granting class certification. We are pleased to answer any questions you might have. Email one of the lawyers listed on this page with any questions.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 12/11/2013
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771